title: Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
authors: Sofia
authors: S
authors: Ghani
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
authors: Omar
authors: O
authors: Al Ustwani
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
authors: Bilal
authors: B
authors: Khalid
authors: Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York.
authors: Paul
authors: P
authors: Bogner
authors: Department of Dermatology, Roswell Park Cancer Institute, Buffalo, New York.
authors: Marcelle
authors: M
authors: Grassi
authors: Department of Dermatology, Roswell Park Cancer Institute, Buffalo, New York.
authors: Jennifer
authors: J
authors: Powell
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
authors: Seema Ali
authors: SA
authors: Bhat
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma; D058252:Necrobiotic Xanthogranuloma / Q000188:drug therapy / Q000473:pathology; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide